Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, a strategic move aimed at enhancing its oncology pipeline with an innovative lentiviral in vivo chimeric antigen receptor T-cell (CAR T) therapy currently in clinical trials for relapsed/refractory multiple myeloma. This acquisition underscores Lilly’s commitment to advancing cancer therapies, particularly as the industry increasingly shifts toward personalized medicine solutions.

Kelonia’s lead program, KLN-1010, is a one-time intravenous gene therapy designed to produce anti-B-cell maturation antigen (BCMA) CAR T cells, targeting the BCMA protein found on multiple myeloma cells. The promising early clinical data presented at the American Society of Hematology (ASH) 2025 Annual Meeting demonstrated a 100% minimal residual disease (MRD)-negative response rate across four patients, indicating significant potential for this therapy.

With FDA clearance for an investigational new drug (IND) application, Kelonia is set to expand its trials into multiple U.S. clinical sites, positioning KLN-1010 as a potential game-changer in multiple myeloma treatment. Lilly’s acquisition may also influence competitive dynamics in the sector, particularly prompting other major players like Johnson & Johnson to reevaluate their oncology portfolios in light of Kelonia’s innovative approaches.